Company Description
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies.
It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103.
Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Cheng Liu |
Contact Details
Address: 5858 Horton Street, Suite 370 EmeryVille, California 94608 United States | |
| Phone | 510 318 9098 |
| Website | estrellabio.com |
Stock Details
| Ticker Symbol | ESLA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1844417 |
| CUSIP Number | 297584104 |
| ISIN Number | US2975841048 |
| Employer ID | 86-1314502 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cheng Liu Ph.D. | Chief Executive Officer, President and Director |
| Jiandong Xu | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 27, 2026 | DEF 14A | Other definitive proxy statements |
| May 18, 2026 | 10-Q | Quarterly Report |
| May 18, 2026 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 15, 2026 | SCHEDULE 13G | Filing |
| Apr 30, 2026 | 10-K/A | [Amend] Annual report |
| Mar 18, 2026 | 10-K | Annual Report |
| Feb 13, 2026 | 424B3 | Prospectus |
| Jan 23, 2026 | EFFECT | Notice of Effectiveness |
| Jan 22, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 16, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |